Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Denali Therapeutics Inc. (DNLI)

22.15 -0.65 (-2.85%)
As of 11:28:32 AM EDT. Market Open.
Trade DNLI on Coinbase
Chart Range Bar
Loading chart for DNLI
  • Previous Close 22.80
  • Open 22.32
  • Bid 16.04 x 200
  • Ask 28.37 x 200
  • Day's Range 22.15 - 22.48
  • 52 Week Range 12.58 - 27.30
  • Volume 239,923
  • Avg. Volume 1,659,436
  • Market Cap (intraday) 3.541B
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -2.84
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 35.75

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

www.denalitherapeutics.com

503

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DNLI
34.16%
S&P 500 (^GSPC)
12.63%

1-Year Return

DNLI
49.76%
S&P 500 (^GSPC)
18.58%

3-Year Return

DNLI
4.98%
S&P 500 (^GSPC)
70.74%

5-Year Return

DNLI
59.38%
S&P 500 (^GSPC)
70.00%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3.6M
Earnings -127.55M
Profit Margin -3,539.21%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-100M
-50M
0
-3000.0%
-2000.0%
-1000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

27.00
35.75 Average
22.15 Current
42.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/25/2026
Analyst B. Riley Securities
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 30 -> 35

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    3.66B

  • Enterprise Value

    2.98B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.16k

  • Price/Book (mrq)

    4.45

  • Enterprise Value/Revenue

    843.45

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.15%

  • Return on Equity (ttm)

    -54.93%

  • Revenue (ttm)

    3.6M

  • Net Income Avi to Common (ttm)

    -511.45M

  • Diluted EPS (ttm)

    -2.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    710.47M

  • Total Debt/Equity (mrq)

    4.51%

  • Levered Free Cash Flow (ttm)

    -268.53M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

22.15 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 01/12/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 01/09/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 07/28/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: